HCV REINFECTION AND INJECTING RISK BEHAVIOR FOLLOWING ELBASVIR/GRAZOPREVIR TREATMENT IN PATIENTS ON OPIOID AGONIST THERAPY: CO-STAR THREE YEAR FOLLOW-UP STUDY

Dore G1, Grebely J1, Altice F2, Litwin AH3, Dalgaard O4, Gane EJ5, Shibolet O6, Luetkemeyer A7, Nahass R8, Peng CY9, Conway B10, Iser DM11, Huang HC12, Gendrano IN12, Kelly M12, Hwang P12, Robertson M12, Wahl J12, Barr E12, & Platt HL12

1UNSW Sydney, NSW, Australia, 2Yale University, New Haven, CT, United States, 3Albert Einstein/Montefiore Medical Center, Bronx, NY, United States, 4Akershus University, Oslo, Norway, 5Auckland City Hospital, Auckland, New Zealand, 6Liver Unit, Department of Gastroenterology, Tel-Aviv Medical Center and Tel-Aviv University, Tel-Aviv, Israel, 7University of California, San Francisco, CA, United States, 8ID Care, Hillsboro, NJ, United States, 9China Medical University Hospital, Taichung, Taiwan, 10Vancouver Infectious Diseases Centre, Victoria, BC, Canada, 11St. Vincent's Hospital, Melbourne, VIC, Australia, 12Merck & Co., Inc., Kenilworth, NJ, United States.

Background:
High rates of efficacy were observed in Co-STAR, a Phase 3 trial of 12 weeks of elbasvir/grazoprevir (EBR; NS5A inhibitor) / (GZR; NS3/4A protease inhibitor) in patients on opioid agonist therapy (OAT). HCV reinfection was observed in 6/296 (2%) of patients between the end of treatment (EOT) and follow-up week 24. The aim of the Co-STAR Three Year Follow-up Study (3YFU) is to evaluate HCV reinfection and injecting risk behaviours in patients treated with EBR/GZR.

Methods:
This 3 year observational cohort study enrolled patients who received at least one dose of EBR/GZR in the Phase 3 trial. Every 6 months, patients are tested for HCV RNA and if detected, viral genotype and sequencing are performed.

Results:
Of 296 patients treated in Co-STAR, 185 patients (63%) were enrolled in the 3YFU. Enrolled patients were generally representative of the parent trial. Sixty percent of patients in the 3YFU study had a positive urine drug screen (UDS) at enrolment. The median time from EOT to the first visit during the 3YFU was 330 days (range: 206-485). Other than the 6 reinfections, two viral recurrences were identified at the first visit during the 3YFU. One patient had GT1a at baseline and GT3 at follow-up, opiates and cannabinoids were detected by UDS. One patient had GT1b at baseline, a HCV RNA (258 IU/mL) detected at the first visit; however, the genotype was unable to be determined (low viral load), no drugs besides OAT were detected by UDS; this patient is not considered a reinfection while additional follow-up is pending. Of the 185 patients in the 3YFU, 108 (58%) reported any drug use (non-injecting or injecting) in the past 6 months. Injecting drug use in the past 6 months was reported by 47 (25%) patients. Of those reporting injecting drug use in the past 6 months, injected drugs included heroin (n=34; 72%), amphetamines (n=8; 17%), cocaine (n=7; 15%), and other opioids (n=7; 15%).

Conclusion:
HCV reinfection among patients on OAT following EBR/GZR treatment is uncommon despite ongoing drug use. Additional follow-up is ongoing.

Disclosure of Interest Statement:
Greg Dore
• Board Membership: Gilead, Merck, Abbvie, Bristol-Myers Squibb
• Grant/Research Support: Gilead, Merck, Abbvie, Bristol-Myers Squibb
• Speaking and Teaching: Gilead, Merck, Abbvie, Bristol-Myers Squibb: